Mp28-15 Long-Term Satisfaction With Collagenase Clostridium Histolyticum for Peyronie's Disease: Clinical Predictors and Side Effect Profile

You have accessJournal of UrologySexual Function/Dysfunction: Peyronie's Disease (MP28)1 May 2024MP28-15 LONG-TERM SATISFACTION WITH COLLAGENASE CLOSTRIDIUM HISTOLYTICUM FOR PEYRONIE'S DISEASE: CLINICAL PREDICTORS AND SIDE EFFECT PROFILE Jeffrey Song, Gal Saffati, Michelle Dai, Taher Naeem, Mohit Khera, and Larry Lipshultz Jeffrey SongJeffrey Song , Gal SaffatiGal Saffati , Michelle DaiMichelle Dai , Taher NaeemTaher Naeem , Mohit KheraMohit Khera , and Larry LipshultzLarry Lipshultz View All Author Informationhttps://doi.org/10.1097/01.JU.0001008872.42208.7a.15AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Collagenase Clostridium histolyticum (CCH) therapy for Peyronie's Disease (PD) yields satisfaction rates of roughly 67% within two years of CCH completion. However, little is known about long-term patient satisfaction with CCH therapy. This study aimed to identify clinical predictors of long-term satisfaction with CCH and the impact of its side effect (SE) profile. METHODS: Patients who received CCH for PD from 2009-2022 underwent chart review and completed a standardized survey using the Treatment Satisfaction Questionnaire for Medication (TSQM). The TSQM is validated across the satisfaction subdomains of effectiveness, SE, convenience, and global satisfaction (GS) that are summed to form the TSQM total. RESULTS: Of 243 CCH recipients, 80 (32.9%) responded, with surveys completed on median 5.1 (IQR 2.4-6.7) years after the last CCH injection. 34 (42.5%) respondents were satisfied with CCH therapy. Older age was associated with significantly higher SE subdomain scores (p<0.004 for all) (Table 1). The curvature degree, plaque diameter, and plaque volume before CCH treatment, and the amount of change in these parameters did not significantly affect TSQM totals. However, patients with greater curvature degree and plaque volume after CCH completion had significantly lower TSQM totals (Spearman's ρ= -0.36, -0.32; p<0.04 for both). 10 (12.5%) patients with depression exhibited significantly decreased scores of the effectiveness and GS subdomains, and TSQM total (p<0.04 for all). 10 (12.5%) patients proceeded to surgery and exhibited significantly lower scores of the effectiveness subdomain and TSQM total (p=0.008, 0.001). On average, patients exhibited 2.2 (SD 1.5) SE, most commonly bruising, swelling, and pain with injection. SE with significantly lower TSQM totals were new erectile dysfunction, hematoma, and pain with injection (p<0.03 for all). CONCLUSIONS: Nearly half of our cohort remained satisfied approximately five years after CCH completion. Additionally, the final curvature and plaque volume were the most notable objective predictors of long-term satisfaction, rather than the degree of change in these parameters. Although pain with injection and hematoma are considered mild to moderate in severity, these SE continue to impact long-term satisfaction. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e478 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Jeffrey Song More articles by this author Gal Saffati More articles by this author Michelle Dai More articles by this author Taher Naeem More articles by this author Mohit Khera More articles by this author Larry Lipshultz More articles by this author Expand All Advertisement PDF downloadLoading ...